Al-Ola Abdallah։ 2nd International Congress on Acute Leukemia, MDS, Immunotherapy and Cellular Therapy in Oran
Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn: “At Oran, Algeria prior…
Read the full articleYou might also wanna read
Dr. Soliman Fakeeh Hospital performs private sector's first stem cell transplant in Saudi Arabia
This achievement reflects the hospital’s continued advancement in specialized hematology and oncology care and reinforces its position as a
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Conditions : T-Cell Acute Lymphoblastic Leukemia; T-Lymphoblastic Lymphoma; Relapsed/Refractory Hematologic Malignancies Interventions : Bio
La junta directiva de OHSU inaugura la era del Knight Cancer Group con aprobación y estructura de gobierno
Una nueva estructura le da al Knight Cancer Institute mayor autoridad y autonomía para crear una experiencia para pacientes de la más alta c
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Conditions : DLBCL - Diffuse Large B Cell Lymphoma Interventions : Drug: Orelabrutinib combined with standard immunochemotherapy with or wit
Cette thérapie permet de transformer les cellules immunitaires en arme contre le cancer grâce à une injection chez la souris
Une avancée majeure en thérapie génique permet de reprogrammer les cellules immunitaires directement dans le corps pour cibler les tumeurs,
La jutgessa de Martorell descarta investigar la terapeuta dels Andic després de la seva declaració
La 'coach' ha declarat durant més de dues hores, com també ho ha fet la viuda del fundador de Mango
ara.cat·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.